# A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

> **NCT05604898** · PHASE2 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 139 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
- **OTHER:** Placebo
- **DRUG:** Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05604898
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-05
- **Final completion:** 2023-08
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05604898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05604898, "A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05604898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*